As of Wednesday close, CRISPR Therapeutics AG’s (NASDAQ:CRSP) stock was down -$1.48, moving down -3.04 percent to $47.20. The average number of shares traded per day over the past five days has been 1,013,420 shares. 1 time new highs have been achieved over the past 5 days, with a -$3.75 fall in that time frame. In the last twenty days, the average volume was 1,098,590, while in the previous 50 days, it was 1,130,952.
Since last month, CRSP stock retreated -18.27%. Shares of the company fell to $47.00 on 08/16/23, the lowest level in the past month. A 52-week high of $80.46 was reached on 05/23/23 after having rallying from a 52-week low of $38.94. Since the beginning of this year, CRSP’s stock price has risen by 16.11% or $6.55, and marked a new high 14 times. However, the stock has declined by -41.34% since its 52-week high.
CRSP stock investors should be aware that CRISPR Therapeutics AG (CRSP) stock had its last reported insider trading activity 79 days ago on May 30. Kulkarni Samarth, the Chief Executive Officer of the company, disposed of 25,000 shares for $64.88 on May 30. It resulted in a $1,621,894 divestment by the insider. Kulkarni Samarth sold 25,000 shares at an average price of $50.67 on Apr 25. The insider now owns 387,377 shares following the transaction. On Mar 29, Chief Executive Officer Kulkarni Samarth sold 25,000 shares at $44.46 apiece. The transaction was valued at $1,111,504.
Valuation Metrics
The stock’s beta is 1.62. Besides these, the trailing price-to-sales (P/S) ratio of 22.22, the price-to-book (PB) ratio of 2.06.
Financial Health
In the three months ended June 29, CRISPR Therapeutics AG’s quick ratio stood at 14.00, while its current ratio was 14.00, showing that the company is able to pay off its debt. Based on annual data, CRSP earned $674.36 million in gross profit and brought in $1.2 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -35.90%. Return on equity (ROE) for the past 12 months was -22.20%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. CRSP’s revenue rose 99.77% during the quarter, while net income inched up to $70.0 million. While analysts expected CRISPR Therapeutics AG to report -$2.12 quarterly earnings, the actual figure was -$0.98 per share, beating the consensus estimate by 53.80%. During the quarter, the company generated -$90.26 million in EBITDA. The liabilities of CRISPR Therapeutics AG were 380.99 million at the end of its most recent quarter ended June 29, and its total debt was $245.18 million. The value of shareholders’ equity is $79.41 million.
Technical Picture
This quick technical analysis looks at CRISPR Therapeutics AG’s (CRSP) price momentum. With a historical volatility rate of 62.85%, the RSI 9-day stood at 30.12% on 16 August.
With respect to its five-day moving average, the current CRISPR Therapeutics AG price is down by -7.36% percent or -$3.75. At present, CRSP shares trade -18.79% below its 20-day simple moving average and +9.41% percent above its 100-day simple moving average. However, the stock is currently trading approximately -25.13% below its SMA50 and -9.85% below its SMA200.
Stochastic coefficient K was 8.79% and Stochastic coefficient D was 12.05%, while ATR was 2.26. Given the Stochastic reading of 1.81% for the 14-day period, the RSI (14) reading has been calculated as 33.32%. As of today, the MACD Oscillator reading stands at -1.60, while the 14-day reading stands at -3.49.
Analyst Ratings
William Blair launched its rating on CRISPR Therapeutics AG (NASDAQ: CRSP) to an Outperform in a note to investors on May 30, 2023. CRISPR Therapeutics AG (CRSP) has been rated Overweight by analysts. According to 2 brokerage firms, CRSP is a sell, and 12 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate CRISPR Therapeutics AG stock as buy, with 15 recommending it as overweight.
With a median target price of $74.50, the current consensus forecast for the stock is $43.00 – $220.00. Based on these forecasts, analysts predict CRISPR Therapeutics AG (CRSP) will achieve an average price target of $85.77.
